Onyx Pharmaceuticals Announces Webcast to Discuss Multiple Myeloma Market and Carfilzomib Clinical Overview

Share Name	Share Symbol	Market	Type
Onyx Pharmaceuticals, Inc. (MM)	NASDAQ:ONXX	NASDAQ	Common Stock

Share Name

Share Symbol

Market

Type

Onyx Pharmaceuticals, Inc. (MM)

NASDAQ:ONXX

NASDAQ

Common Stock

Price Change

% Change

Share Price

Bid Price

Offer Price

High Price

Low Price

Open Price

Shares Traded

Last Trade

0.00

0.00%

124.70

01:00:00

Onyx Pharmaceuticals Announces Webcast to Discuss Multiple Myeloma Market and Carfilzomib Clinical Overview

12/10/2009 1:00pm

PR Newswire (US)

Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart

From Jul 2019 to Jul 2024

Click Here for more Onyx Pharmaceuticals, Inc. (MM) Charts.

Webcast to Take Place at 11:00 a.m. ET Today, October 12 EMERYVILLE, Calif., Oct. 12 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that it will host a webcast, led by external medical experts, to discuss the multiple myeloma market and provide an overview of the carfilzomib clinical program. The webcast will take place today at 11:00 a.m. ET, and can be accessed at http://www.onyx-pharm.com/view.cfm/32/Event-Calendar. The event follows the announcement of Onyx's intention to acquire Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors. Proteolix's lead compound, carfilzomib, is a next generation proteasome inhibitor that is currently in multiple clinical trials, including an advanced Phase 2b clinical trial for patients with relapsed and refractory multiple myeloma. About Onyx Pharmaceuticals, Inc. Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar®, a small molecule drug. Nexavar is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com/. Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals. DATASOURCE: Onyx Pharmaceuticals, Inc. CONTACT: Alex Santos, +1-510-597-6504, for Onyx Pharmaceuticals, Inc. Web Site: http://www.onyx-pharm.com/

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

ONXX Onyx Pharmaceuticals, Inc. (MM)